TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17873686
Drug: XR-NTX 190
Normalized name: metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XR-NTX 190 mg
Study: 30587520
Drug: Ventro-oral thalamotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventro-oral thalamotomy
Study: 24861134
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of warfarin on Day 1
Study: 18311852
Drug: Established treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established treatment
Study: 17198588
Drug: Standardized Tertiary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized Tertiary Rehabilitation (STR) including physical therapy and occupational therapy (OT)
Study: 17198588
Drug: Routine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine intervention of internal medicine (Control)
Study: 24802206
Drug: Intensified Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified Conventional Treatment (ICT)
Study: 4089188
Drug: Sulpiride 10
Normalized name: sulpiride 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 10 mg
Study: 4089188
Drug: Sulpiride 20
Normalized name: sulpiride 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 20 mg
Study: 4089188
Drug: Arginine HCl
Normalized name: arginine HCl
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine HCl infusion (0.33G/kg)
Study: 24074713
Drug: High-dose aspartate-ornithine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspartate-ornithine granules (6 g bid po)
Study: 24074713
Drug: Low-dose aspartate-ornithine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspartate-ornithine granules (3 g bid po)
Study: 21437745
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral information plus an information leaflet about SSI (group O/L)
Study: 21437745
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral information alone (group O)
Study: 18534421
Drug: Portable, continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portable, continuous enhanced circulation therapy (CECT) + low-molecular-weight heparin (LMWH)
Study: 12119640
Drug: Greater initial
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater initial weight loss induced without changes in lifestyle (e.g. liquid formula diets or anorectic drugs)
Study: 12119640
Drug: 1-2 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 years integrated weight maintenance programme consisting of lifestyle interventions (dietary change, nutritional education, behaviour therapy, increased physical activity)
Study: 8682976
Drug: Amitriptyline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (150 mg/day) + sleep deprivation (6 treatments at 4-5 day intervals)
Study: 22987495
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy
Study: 25341682
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (regular medical treatment)
Study: 24135530
Drug: MCI-186 (edaravone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCI-186 (edaravone) with a loading dose of 0.08 mg/kg + 0.2 mg/kg/h infusion
Study: 24135530
Drug: MCI-186 (edaravone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCI-186 (edaravone) with a loading dose of 0.16 mg/kg + 0.4 mg/kg/h infusion
Study: 16980316
Drug: Acupuncture (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (10 individualised treatments)
Study: 8433884
Drug: Glucose with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose with amino acids (1.5 g.kg‐1.d‐1) i.v.
Study: 3127815
Drug: doxycycline 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxycycline 0.1 g x 2
Study: 3127815
Drug: demethylchlortetracycline (DMCT)
Normalized name: Demethylchlortetracyclin
DrugBank: Demeclocycline (DB00618)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: demethylchlortetracycline (DMCT) 0.3 g x 2
Study: 3127815
Drug: lymecycline 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: lymecycline 0.6 g x 2
Study: 18394765
Drug: LJEV administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: LJEV administered at age of 8 months and MV at 9 months (Group 1)
Study: 20852004
Drug: Pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 20 mg once daily
Study: 8561641
Drug: CP-treated group
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-treated group (St. Thomas' Hospital cardioplegic solution No. 1 plus CP 10 mmol/L)
Study: 8561641
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (St. Thomas' Hospital cardioplegic solution No. 1)
Study: 1871547
Drug: Bedtime UDCA
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime UDCA 7 mg/kg/day
Study: 1871547
Drug: Mealtime UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mealtime UDCA 10 mg/kg/day
Study: 1871547
Drug: Bedtime UDCA
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime UDCA (average minimum effective dose) 8.4 mg/kg/day
Study: 1871547
Drug: Repeated-release tablet
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated-release tablet formulation of UDCA
Study: 6221200
Drug: THIP (4,5,6,7‐tetrahydroisoxazolo‐[5,4,‐c]
Approvals — FDA: no, EMA: no, PMDA: no
Description: THIP (4,5,6,7‐tetrahydroisoxazolo‐[5,4,‐c] pyridin‐3‐ol) administered orally for 2 weeks
Study: 6221200
Drug: High-dose THIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose THIP therapy
Study: 30059193
Drug: AAA tablet
Normalized name: JNJ-63839880-AAA
DrugBank: MVA-mBN226B (DB17780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAA tablet
Study: 30059193
Drug: NXA tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXA tablet
Study: 6885201
Drug: Both tablet
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both tablet formulations
Study: 18580553
Drug: Continuation pharmacotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation pharmacotherapy
Study: 21974759
Drug: valsartan/HCTZ 160/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan/HCTZ 160/12.5 mg
Study: 3382038
Drug: Edrophonium 0.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.67 mg/kg with atropine doses ranging from 0.0125 to 0.0215 mg/kg (group A, n = 37)
Study: 3382038
Drug: Edrophonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1.0 mg/kg with atropine doses ranging from 0.02 to 0.04 mg/kg (group B, n = 35)
Study: 26712409
Drug: Population pharmacokinetic
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Population pharmacokinetic model for morphine after oral administration of DTO
Study: 20860867
Drug: Cognitive Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Enhancement Therapy (CET)
Study: 12556006
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 mcg twice daily
Study: 12544410
Drug: Nelfinavir (part
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir (part of dual nucleoside reverse transcriptase inhibitor therapy)
Study: 12544410
Drug: Full adherence
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full adherence to prescribed medication
Study: 8898461
Drug: Integrated control
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated control measures including health education, sanitation, environmental management, and chemotherapy
Study: 23882088
Drug: Ibuprofen, Acetaminophen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, Acetaminophen, Placebo
Study: 20581724
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg for 5 weeks
Study: 18076221
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (n = 25) - Stepwise periodized resistance exercise program + additional rotational and full-body medicine ball exercises, 3 days/week for 12 weeks
Study: 16219016
Drug: Once-daily gliclazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily gliclazide MR
Study: 16219016
Drug: Twice-daily glibenclamide
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily glibenclamide
Study: 2502074
Drug: Sunfural S
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunfural S (new oral form)
Study: 2502074
Drug: Sunfural Rectal
Normalized name: Furfural
DrugBank: Furfural (DB16856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunfural Rectal Capsules (new soft-capsule suppository form)
Study: 2502074
Drug: existing drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: existing drugs
Study: 30359764
Drug: Pre-emptive analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive analgesia with paracetamol (P), ketorolac (K), and pregabalin (PR) administered 4 hours before surgery
Study: 25885548
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention with a neurotrophic dietary supplement
Study: 19744717
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (6 biannual mass treatments)
Study: 29045995
Drug: Carbohydrate‐electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐electrolyte solution (CES)
Study: 15551195
Drug: mCPP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mCPP infusion (serotonin agonist)
Study: 24621122
Drug: Formulation containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation containing 10 mg lutein, 10 mg meso-zeaxanthin, 2 mg zeaxanthin, 500 mg vitamin C, 400 IU vitamin E, 25 mg zinc, and 2 mg copper (Intervention A; Trial 2)
Study: 24621122
Drug: Formulation containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation containing 10 mg lutein and 2 mg zeaxanthin, 500 mg vitamin C, 400 IU vitamin E, 25 mg zinc, and 2 mg copper (Intervention B; Trial 2)
Study: 17405895
Drug: Glutamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (15 g twice a day for seven consecutive days every 2 weeks starting on the day of oxaliplatin infusion)
Study: 1335221
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (four logarithmically increasing doses)
Study: 6145734
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam
Study: 28418482
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg, single oral dose)
Study: 25613634
Drug: Yiqi Houxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Houxue Bushen Decoction (treatment group)
Study: 17156466
Drug: Pre-pregnancy intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-pregnancy intervention provided by midwives, including discussions on social, health or lifestyle problems, preparation and timing for pregnancy, family history, rubella immunisation, referrals for health problems, and a reminder card.
Study: 24879552
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy exercise program
Study: 18794207
Drug: Olanzapine (2.5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5-20 mg/day)
Study: 18594050
Drug: Candesartan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (6 months treatment)
Study: 10189126
Drug: Concurrent 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent 5-fluorouracil (5-FU)
Study: 7485297
Drug: Hospital-compounded formulation
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-compounded formulation of 0.5 mg of prostaglandin E2 gel
Study: 2218419
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg b.i.d. for seven days
Study: 2218419
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg b.i.d. for seven days
Study: 31477061
Drug: Standard model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard model of family psychoeducation (SM-FPE) plus treatment as usual (TAU)
Study: 26867542
Drug: Continuing acute
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing acute noninvasive ventilation as a long-term therapy
Study: 11377645
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a 22 microg subcutaneously once weekly for 2 years
Study: 9555794
Drug: Acidified nitrite
Normalized name: Nitrite
DrugBank: Nitrite (DB12529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidified nitrite cream (3% salicylic acid in aqueous cream and 3% nitrite in aqueous cream) applied twice daily for 4 weeks
Study: 27528067
Drug: Autonomic blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autonomic blockade (trimethaphan 4 mg/min IV)
Study: 24734184
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg oral misoprostol (as two tablets) and 2 mL normal saline in 1000 mL Ringer's solution
Study: 24734184
Drug: 20 IU
Normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU of oxytocin in 1000 mL Ringer's solution and two placebo tablets
Study: 20456355
Drug: Vorinostat (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (400 mg TID for 3 days) in combination with idarubicin
Study: 18593524
Drug: VPA DR
Normalized name: Dr. Numb
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA DR soft gelatin capsule (500 mg), non-fasting
Study: 16202734
Drug: Intra-amniotic PGF2alpha
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic PGF2alpha (carboprost 1.5 mg)
Study: 9182114
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg bd for three days
Study: 9182114
Drug: Norfloxacin 800
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 800 mg as a single dose
Study: 9182114
Drug: Multidose norfloxacin
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidose norfloxacin treatment
Study: 2161578
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral + intramuscular estrogens
Study: 2161578
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug intramuscular estrogens
Study: 16413878
Drug: Zinc alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc alone (10 mg)
Study: 11528551
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cytarabine and mitoxantrone (HAM)
Study: 19506
Drug: Single graded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single graded intramuscular doses of morphine test
Study: 19506
Drug: Single graded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single graded intramuscular doses of morphine standard
Study: 19903574
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 300 mg once daily
Study: 21371314
Drug: Prolonged conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged conservative treatment (further treatment from general practitioner and physical therapist)
Study: 16757722
Drug: Clinical pathway
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pathway treatment
Study: 14707554
Drug: 546C88 (nitric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 546C88 (nitric oxide synthase inhibitor)
Study: 11334121
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education intervention consisting of two 2-hour group sessions followed by 1-2 individual sessions administered by a nurse and a physiotherapist, emphasizing self-management
Study: 9013165
Drug: Prior medical
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior medical therapy
Study: 8525817
Drug: Tenoxicam 10
Normalized name: tenoxicam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 10 mg daily for 6 weeks
Study: 8525817
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg daily for 6 weeks
Study: 2691121
Drug: Pirenzepine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (200 mg p.o.)
Study: 30526266
Drug: Corrective exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corrective exercise program based on National Academy of Sport Medicine guidelines
Study: 31446638
Drug: PEG‐IFN-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN-based therapy
Study: 31446638
Drug: Baseline HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline HBV RNA (cut-off 2.0 log10 copies/mL)
Study: 22078152
Drug: Acarbose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (50 mg TID for 4 weeks, then 100 mg TID for 12 weeks)
Study: 22078152
Drug: Glibenclamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (2.5 mg TID for 4 weeks, then 5 mg TID for 12 weeks)
Study: 19909879
Drug: Combined dose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dose group of Ambrisentan
Study: 16510054
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 0.5 cc lidocaine 1% plus methylprednisolone acetate (Depo-Medrol) 40 mg
Study: 15131559
Drug: Cardiac rehabilitation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac rehabilitation and prevention program (CRPP) - 2-hour twice-weekly exercise program for 8 weeks
Study: 9587651
Drug: Erythromycin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (100 mg or 500 mg intravenously)
Study: 1320559
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical therapy
Study: 29228247
Drug: ASP8477 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8477 (all doses)
Study: 27861191
Drug: Levomilnacipran extended-release
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomilnacipran extended-release (ER) 40-120 mg/day
Study: 16519552
Drug: 0.03% bimatoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% bimatoprost ophthalmic solution once daily
Study: 23997106
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg)
Study: 24812896
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine therapy)
Study: 20124229
Drug: Diclofenac, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac, 50 mg, twice daily for 14 days
Study: 10510993
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein with 62 mg of isoflavones
Study: 10510993
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein with 37 mg of isoflavones
Study: 10510993
Drug: Ethanol-extracted isolated
Normalized name: Serenoa Repens Fruit Ethanol Extract
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol-extracted isolated soy protein containing 3 mg of isoflavones
Study: 8748255
Drug: IL-10 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-10 (single intravenous injection)
Study: 1889712
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg) + Pepto‐Bismol (bismuth salicylate)
Study: 1889712
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg) + Roter (bismuth subnitrate)
Study: 27173580
Drug: Ozone gas
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone gas (32 g m-3)
Study: 20144171
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (50 microg)
Study: 14616254
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (100 microg)
Study: 3880523
Drug: Atropine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.04 mg/kg i.v.)
Study: 7733345
Drug: Propranolol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.2 mg/kg i.v.)
Study: 7214807
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g fractionated dose of iopanoic acid (Telepaque)
Study: 26034931
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of moxifloxacin per os once daily for 7 days
Study: 26034931
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of metronidazole and 500 mg amoxicillin per os three times daily for 7 days
Study: 12671775
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy provided at different study centers
Study: 10993428
Drug: Pantoprazole (Pan)
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole (Pan) 80 mg O.D. for 1 week with clarithromycin (Cla) 500 mg B.I.D. and amoxicillin (Amo) 1 g B.I.D. for 5 days
Study: 10993428
Drug: Omeprazole (Ome)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (Ome) 40 mg O.D. for 1 week with clarithromycin (Cla) 500 mg B.I.D. and amoxicillin (Amo) 1 g B.I.D. for 5 days